2017, Number S1
<< Back Next >>
Rev Mex Anest 2017; 40 (S1)
Use of opioids and cannabinoids in chronic pain
Ramos-Alaniz A, Guajardo-Rosas J, Chejne-Gómez F, Juárez-Lemus ÁM, Ayón-Villanueva H
Language: Spanish
References: 6
Page: 5-7
PDF size: 149.08 Kb.
Text Extraction
No abstract.
REFERENCES
— Torres LM, Trinidad JM, Calderón E. Potencial terapéutico de los cannabinoides. Rev Soc Esp Dolor. 2013;20:132-136.
— Moulin D, Boulanger A, Clark AJ, Clarke H, Dao T, Finley GA, et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014;19:328-335.
— Deshpande A, Mailis-Gagnon A, Zoheiry N, Lakha SF. Efficacy and adverse effects of medical marijuana for chronic noncancer pain: systematic review of randomized controlled trials. Can Fam Physician. 2015;61:e372-e381.
— de Vries M, Van Rijckevorsel DC, Vissers KC, Wilder-Smith OH, Van Goor H. Single dose delta-9-tetrahydrocannabinol in chronic pancreatitis patients: analgesic efficacy, pharmacokinetics and tolerability. Br J Clin Pharmacol. 2016;81:525-537.
— Kapur BM, Lala PK, Shaw JL. Pharmacogenetics of chronic pain management. Clin Biochem. 2014;47:1169-1187.
— González-Escalada JR. La sinergia farmacológica aplicada a la analgesia: revisión de la combinación de ibuprofeno con codeína. Rev Soc Esp Dolor. 2010;17:51-60.
Full text